Mouse embryonic stem cells (mESCs) have long stood as a cornerstone of regenerative medicine and developmental biology research. Derived from the inner cell mass of blastocyst-stage mouse embryos, these cells possess two defining characteristics: pluripotency, the ability to differentiate into any cell type in the adult body, and self-renewal, the capacity to divide indefinitely while maintaining that pluripotent state. Harnessing these properties, however, requires precise control over the cellular signaling pathways that govern mESC fate. This is where SB431542, a small molecule inhibitor, emerges as a powerful tool—one that has revolutionized how researchers manipulate mESCs in the lab. [Read more…]
Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research
Kyoto University has announced that it will start providing human embryonic stem cells (ES cells) by July 2018 to universities and companies within Japan for clinical trial applications. This is a world-first, as most countries have been hesitant to support wide-spread production and distribution of this controversial cell type.
Previously Japan limited the use of human embryonic stem cells to basic research, because the cells are produced from human embryos, making them a highly controversial cell type. In 2014, the Japanese government revised it guidelines, making possible the use human ES cells in clinical studies, as well as laboratory research. [Read more…]